Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
20
6
2020
medline:
7
10
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Adrenomedullin is a vasoactive peptide that improves endothelial barrier function in sepsis, but may also cause hypotension and organ failure. Treatment with a non-neutralizing monoclonal anti-adrenomedullin antibody showed improvement in murine sepsis models. We tested the effects of the humanized monoclonal anti-adrenomedullin antibody Adrecizumab in a porcine two-hit model of hemorrhagic and septic shock.In this randomized, blinded study 12 German Landrace pigs were bled to half of baseline mean arterial pressure for 45 min. Sepsis was induced using an Escherichia coli clot placed into the abdominal cavity 6 h after hemorrhagic shock. Animals received either 2 mg/kg BW anti-adrenomedullin antibody or vehicle solution immediately after sepsis induction. After 4 h, resuscitation was initiated using balanced crystalloids and noradrenalin to maintain a central venous pressure of 8 to 12 mm Hg, a mean arterial pressure ≥ 65 mm Hg, and a ScvO2 ≥70% for another 8 h. Hemodynamic parameters, laboratory parameters, and kidney histology were assessed.The amount of volume resuscitation was significantly lower and significantly less animals developed a septic shock in the antibody-treated group, compared with the vehicle group. Kidney histology showed significantly lower granulocytes in both cortex and medulla in antibody-treated animals, while the remaining four kidney measures (serum creatinine and urine output and cortical and medullary injury in histopathology) did not reach the significance levels. After induction of sepsis, plasma adrenomedullin increased immediately in both the groups, but increased quicker and more pronounced in the antibody group.In this two-hit shock model, treatment with an anti-adrenomedullin antibody significantly increased plasma adrenomedullin levels, while significantly less animals developed septic shock and renal granulocyte extravasation was significantly reduced. Thus, therapy with Adrecizumab may provide benefit in sepsis, and clinical investigation of this drug candidate is warranted.
Identifiants
pubmed: 32554994
doi: 10.1097/SHK.0000000000001587
pii: 00024382-202012000-00014
doi:
Substances chimiques
Adrenomedullin
148498-78-6
Antibodies, Monoclonal, Humanized
0
enibarcimab
K2IB8MBP1A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
810-818Références
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8):801–810, 2016.
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395 (10219):200–211, 2020.
Stoller J, Halpin L, Weis M, Aplin B, Qu W, Georgescu C, Nazzal M. Epidemiology of severe sepsis: 2008–2012. J Crit Care 31 (1):58–62, 2016.
Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41 (5):1167–1174, 2013.
Group SCCT. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med 42 (12):1980–1989, 2016.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 43 (3):304–377, 2017.
Vincent JL. The rise and fall of drotrecogin alfa (activated). Lancet Infect Dis 12 (9):649–651, 2012.
Yang S, Zhou M, Chaudry IH, Wang P. Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1. Ann Surg 236 (5):625–633, 2002.
Temmesfeld-Wollbruck B, Brell B, David I, Dorenberg M, Adolphs J, Schmeck B, Suttorp N, Hippenstiel S. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med 33 (4):703–710, 2007.
Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol 168 (6):1921–1930, 2006.
Zhou M, Maitra SR, Wang P. Adrenomedullin and adrenomedullin binding protein-1 protect endothelium-dependent vascular relaxation in sepsis. Mol Med 13 (9–10):488–494, 2007.
Wu R, Higuchi S, Dong W, Ji Y, Zhou M, Marini CP, Ravikumar TS, Wang P. Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein. Mol Med 15 (1–2):28–33, 2009.
Geven C, Bergmann A, Kox M, Pickkers P. Vascular effects of adrenomedullin and the anti-adrenomedullin antibody adrecizumab in sepsis. Shock 50:132–140, 2018.
Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, Marumo F. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 81 (4):1449–1453, 1996.
Ueda S, Nishio K, Minamino N, Kubo A, Akai Y, Kangawa K, Matsuo H, Fujimura Y, Yoshioka A, Masui K, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 160 (1):132–136, 1999.
Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, Cavana M, Tognoni G, Pesenti A, Gattinoni L, et al. Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. Chest 152 (2):312–320, 2017.
Simon TP, Martin L, Doemming S, Humbs A, Bruells C, Kopp R, Hartmann O, Struck J, Bergmann A, Marx G, et al. Plasma adrenomedullin in critically ill patients with sepsis after major surgery: a pilot study. J Crit Care 38:68–72, 2017.
Struck J, Hein F, Karasch S, Bergmann A. Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model. Intensive Care Med Exp 1:22, 2013.
Wagner K Ulrich, Vogt JA, Scheuerle A, McCook O, Weber S, Gröger M, Stahl B, Georgieff M, Möller P, Bergmann A, et al. Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock. J Softw Eng Res Dev 1:2, 2013.
Geven C, Peters E, Schroedter M, Struck J, Bergmann A, McCook O, Radermacher P, Kox M, Pickkers P. Effects of the humanized anti-adrenomedullin antibody Adrecizumab (HAM8101) on vascular barrier function and survival in rodent models of systemic inflammation and sepsis. Shock 50:648–654, 2018.
Blet A, Deniau B, Geven C, Sadoune M, Caillard A, Kounde PR, Polidano E, Pickkers P, Samuel JL, Mebazaa A. Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats. Intensive Care Med Exp 7 (1):25, 2019.
Simon TP, Schuerholz T, Hüter L, Sasse M, Heyder F, Pfister W, Marx G. Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study. Crit Care 16 (1):R16, 2012.
Simon TP, Thiele C, Schuerholz T, Fries M, Stadermann F, Haase G, Amann KU, Marx G. Molecular weight and molar substitution are more important in HES-induced renal impairment than concentration after hemorrhagic and septic shock. Minerva Anestesiol 81 (6):608–618, 2015.
Turnbull RG, Talbot JA, Hamilton SM. Hemodynamic changes and gut barrier function in sequential hemorrhagic and endotoxic shock. J Trauma 38 (5):705–712, 1995.
Eissner B, Matz K, Smorodchenko A, Röschmann A, v Specht BU. Chronic porcine two-hit model with hemorrhagic shock and Pseudomonas aeruginosa sepsis. Eur Surg Res 34 (1–2):61–67, 2002.
Abraham E, Jesmok G, Tuder R, Allbee J, Chang YH. Contribution of tumor necrosis factor-alpha to pulmonary cytokine expression and lung injury after hemorrhage and resuscitation. Crit Care Med 23 (8):1319–1326, 1995.
Cué JI, Peyton JC, Malangoni MA. Does blood transfusion or hemorrhagic shock induce immunosuppression? J Trauma 32 (5):613–617, 1992.
Geven C, Kox M, Pickkers P. Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol 9:292, 2018.
Geven C, van Lier D, Blet A, Peelen R, Ten Elzen B, Mebazaa A, Kox M, Pickkers P. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects. Br J Clin Pharmacol 84 (9):2129–2141, 2018.
Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care 18 (1):R34, 2014.
Weber J, Sachse J, Bergmann S, Sparwaßer A, Struck J, Bergmann A. Sandwich Immunoassay for Bioactive Plasma Adrenomedullin [in press]. J Appl Lab Med 2:222–233, 2017.
ACCP, SCCM: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (6):864–874, 1992.
Keppler U, Schmoch T, Siegler BH, Weigand MA, Uhle F. Implementation of the Sepsis-3 definition in German university intensive care units: a survey. Anaesthesist 67 (9):647–653, 2018.
Hernández G, Machado F, Ospina-Tascón G. Defining septic shock. JAMA 316 (4):454–455, 2016.
Jaehne AK, Jayaprakash N, Langberg S. Defining septic shock. JAMA 316 (4):455, 2016.
Schneider-Lindner V, Lindner HA, Thiel M. Definitions for sepsis and septic shock. JAMA 316 (4):457, 2016.
Müller-Redetzky HC, Will D, Hellwig K, Kummer W, Tschernig T, Pfeil U, Paddenberg R, Menger MD, Kershaw O, Gruber AD, et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. Crit Care 18 (2):R73, 2014.
Geven C, Kox M, Scigalla P, Bergmann A, Peters E, Pickkers P. Safety, tolerability and pharmacokinetics/-dynamics of the anti-adrenomedullin antibody adrecizumab: a first in man study. Intensive Care Med Exp 5: (suppl 2): 0427, 2017.
Ertmer C, Morelli A, Rehberg S, Lange M, Hucklenbruch C, Van Aken H, Booke M, Westphal M. Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia. Br J Anaesth 99 (6):830–836, 2007.
Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 85 (3):1016–1020, 2000.
Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 95 (5):1214–1221, 1997.
Parkes DG, May CN. Direct cardiac and vascular actions of adrenomedullin in conscious sheep. Br J Pharmacol 120 (6):1179–1185, 1997.
Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krull M, Seybold J, Seeger W, Rascher W, Schutte H, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 91 (7):618–625, 2002.
Brell B, Temmesfeld-Wollbrück B, Altzschner I, Frisch E, Schmeck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med 33 (4):819–826, 2005.
Hocke AC, Temmesfeld-Wollbrueck B, Schmeck B, Berger K, Frisch EM, Witzenrath M, Brell B, Suttorp N, Hippenstiel S. Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: inhibition of endothelial gap formation by adrenomedullin. Histochem Cell Biol 126 (3):305–316, 2006.
Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc Natl Acad Sci U S A 98 (2):615–619, 2001.
Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, Bloom SR. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82 (1):95–100, 1997.
Lewis LK, Smith MW, Brennan SO, Yandle TG, Richards AM, Nicholls MG. Degradation of human adrenomedullin(1-52) by plasma membrane enzymes and identification of metabolites. Peptides 18 (5):733–739, 1997.
Martínez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 (pt 3):413–418, 2004.
Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 275 (3 Pt 2):F410–414, 1998.